ISPE and PDA have performed a detailed analysis of their two key initiatives ‘PQLI’ and ‘PCMO’ in order to ensure coordination and prevent unnecessary duplication. As a result, program leaders have determined that there is no significant overlap between the efforts of each organization. In those cases where overlap has been identified, agreement was reached to realign the scope and to work together to avoid any duplication of effort.
In summary, both ISPE and PDA have agreed that the PQLI and PCMO deliverables are:
With this in mind, we are determined to utilize the expertise of two organizations to find practical approaches for the changing pharmaceutical environment according to the new paradigm laid down in ICH Q8 (Q11), Q9 and Q10.
Accepting Nominations for 2017-2019 International Board of Directors
Monday, 27 Mar 2017 14.03
Data Integrity: Do You GAMP?
Friday, 24 Mar 2017 13.03
Nominate Your Facility for 2018 Facility of the Year Awards
Thursday, 23 Mar 2017 18.03